NIH #5K12CA088084-24
Paul Calabresi Clinical Oncology Award
Active
- Amount
- $805K
- Period
- 2000-09-13 → 2027-06-30
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5K12CA088084-23
Paul Calabresi Clinical Oncology Award
Active
- Amount
- $570K
- Period
- 2000-09-13 → 2027-06-30
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5K12CA088084-22
Paul Calabresi Clinical Oncology Award
Active
- Amount
- $663K
- Period
- 2000-09-13 → 2027-06-30
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5P30CA016672-49
12 Clinical and Translational Research Center
- Amount
- $379K
- Period
- 1996-08-28 → 2026-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #4P30CA016672-48
12 Clinical and Translational Research Center
- Amount
- $357K
- Period
- 1996-08-28 → 2026-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA242565-06
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy
- Amount
- $219K
- Period
- 2019-06-05 → 2025-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA242565-05
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy
- Amount
- $341K
- Period
- 2019-06-05 → 2025-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA242565-04
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy
- Amount
- $147K
- Period
- 2019-06-05 → 2025-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA242565-03
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy
- Amount
- $359K
- Period
- 2019-06-05 → 2024-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA242565-02
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy
- Amount
- $366K
- Period
- 2019-06-05 → 2024-11-30
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5P30CA016672-47
12 Clinical and Translational Research Center
- Amount
- $336K
- Period
- 1996-08-28 → 2024-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5P30CA016672-46
12 Clinical and Translational Research Center
- Amount
- $336K
- Period
- 1996-08-28 → 2024-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #1R01CA242565-01
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy
- Amount
- $366K
- Period
- 2019-06-05 → 2024-05-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA187238-05
Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer
- Amount
- $332K
- Period
- 2014-08-04 → 2020-07-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA187238-04
Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer
- Amount
- $332K
- Period
- 2014-08-04 → 2019-07-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA187238-03
Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer
- Amount
- $332K
- Period
- 2014-08-04 → 2019-07-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA187238-02
Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer
- Amount
- $332K
- Period
- 2014-08-04 → 2019-07-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #1R01CA187238-01
Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer
- Amount
- $332K
- Period
- 2014-08-04 → 2019-07-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR